Literature DB >> 27021338

Dramatic improvement of anti-SS-A/Ro-associated interstitial lung disease after immunosuppressive treatment.

Caramaschi Paola1, Festi Giuliana2, Orsolini Giovanni3, Caimmi Cristian3, Biasi Domenico3.   

Abstract

The aim of the study was to report three patients affected by interstitial lung disease associated with positive anti-SS-A/Ro autoantibody who showed a dramatic improvement after immunosuppressive treatment. Medical charts were reviewed to obtain clinical data, laboratory parameters, lung function tests, high-resolution computed tomography results and response to immunosuppressive treatment. The three patients showed a clinical picture of a lung-dominant connective tissue disease characterized by a sudden onset with dyspnea, cough and subtle extrathoracic features together with positive anti-SS-A/Ro antibody and weak titer antinuclear antibodies. All three patients responded favorably to immunosuppressive therapy: Two cases were treated with a combination of corticosteroid and cyclophosphamide followed by mycophenolate mofetil; in the third patient, clinical benefit was obtained after rituximab was added to corticosteroid and immunosuppressant drug. In spite of an abrupt onset with significant lung function impairment, all three patients had a favorable clinical response to immunosuppressive therapy. This report may be useful in making therapeutic decisions in case of interstitial lung disease associated with anti-SS-A antibody.

Entities:  

Keywords:  Anti-SS-A/Ro autoantibody; Immunosuppressive treatment; Interstitial lung disease

Mesh:

Substances:

Year:  2016        PMID: 27021338     DOI: 10.1007/s00296-016-3463-x

Source DB:  PubMed          Journal:  Rheumatol Int        ISSN: 0172-8172            Impact factor:   2.631


  20 in total

Review 1.  Classification criteria for Sjögren's syndrome: a revised version of the European criteria proposed by the American-European Consensus Group.

Authors:  C Vitali; S Bombardieri; R Jonsson; H M Moutsopoulos; E L Alexander; S E Carsons; T E Daniels; P C Fox; R I Fox; S S Kassan; S R Pillemer; N Talal; M H Weisman
Journal:  Ann Rheum Dis       Date:  2002-06       Impact factor: 19.103

Review 2.  Interstitial lung disease in the connective tissue diseases.

Authors:  Danielle Antin-Ozerkis; Ami Rubinowitz; Janine Evans; Robert J Homer; Richard A Matthay
Journal:  Clin Chest Med       Date:  2012-03       Impact factor: 2.878

3.  Idiopathic interstitial lung disease with anti-SSA antibody.

Authors:  Jean-François Boitiaux; Marie-Pierre Debray; Pascale Nicaise-Roland; Homa Adle-Biassette; Claire Danel; Christine Clérici; Michel Aubier; Xavier Mariette; Jacques Cadranel; Bruno Crestani
Journal:  Rheumatology (Oxford)       Date:  2011-10-08       Impact factor: 7.580

4.  Connective tissue disease-associated interstitial lung disease: a call for clarification.

Authors:  Aryeh Fischer; Sterling G West; Jeffrey J Swigris; Kevin K Brown; Roland M du Bois
Journal:  Chest       Date:  2010-08       Impact factor: 9.410

5.  Long-term experience with rituximab in anti-synthetase syndrome-related interstitial lung disease.

Authors:  Helena Andersson; Marthe Sem; May Brit Lund; Trond Mogens Aaløkken; Anne Günther; Ragnhild Walle-Hansen; Torhild Garen; Øyvind Molberg
Journal:  Rheumatology (Oxford)       Date:  2015-03-03       Impact factor: 7.580

6.  In patients with antisynthetase syndrome the occurrence of anti-Ro/SSA antibodies causes a more severe interstitial lung disease.

Authors:  R La Corte; A Lo Mo Naco; A Locaputo; F Dolzani; F Trotta
Journal:  Autoimmunity       Date:  2006-05       Impact factor: 2.815

7.  Rituximab therapy in patients with refractory dermatomyositis or polymyositis: differential effects in a real-life population.

Authors:  Leonore Unger; Susanne Kampf; Kirsten Lüthke; Martin Aringer
Journal:  Rheumatology (Oxford)       Date:  2014-04-04       Impact factor: 7.580

8.  Effect and safety of mycophenolate mofetil or sodium in systemic sclerosis-associated interstitial lung disease: a meta-analysis.

Authors:  Argyris Tzouvelekis; Nikolaos Galanopoulos; Evangelos Bouros; George Kolios; George Zacharis; Paschalis Ntolios; Andreas Koulelidis; Anastasia Oikonomou; Demosthenes Bouros
Journal:  Pulm Med       Date:  2012-05-10

9.  Lung-dominant connective tissue disease among patients with interstitial lung disease: prevalence, functional stability, and common extrathoracic features.

Authors:  Daniel Antunes Silva Pereira; Olívia Meira Dias; Guilherme Eler de Almeida; Mariana Sponholz Araujo; Letícia Barbosa Kawano-Dourado; Bruno Guedes Baldi; Ronaldo Adib Kairalla; Carlos Roberto Ribeiro Carvalho
Journal:  J Bras Pneumol       Date:  2015 Mar-Apr       Impact factor: 2.624

10.  Experience with rituximab in scleroderma: results from a 1-year, proof-of-principle study.

Authors:  Dimitrios Daoussis; Stamatis-Nick C Liossis; Athanassios C Tsamandas; Christina Kalogeropoulou; Alexandra Kazantzi; Chaido Sirinian; Maria Karampetsou; Georgios Yiannopoulos; Andrew P Andonopoulos
Journal:  Rheumatology (Oxford)       Date:  2009-05-15       Impact factor: 7.580

View more
  1 in total

1.  Ro-positive interstitial lung disease treated with cyclophosphamide.

Authors:  Nader Habib Bedwani; Natasha Jefferson; Christopher Marguerie; Jayanta Mukherjee
Journal:  BMJ Case Rep       Date:  2018-05-22
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.